FDA Ends Emergency Use for One COVID Test
Published Date: 8/15/2025
Notice
Summary
The FDA is ending the emergency approval for LumiraDx’s COVID-19 test because the company asked them to. This means the test can no longer be used for quick COVID-19 diagnosis. If you use or sell this test, you’ll need to stop soon, but no extra costs or penalties are mentioned.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
LumiraDx COVID Test Authorization Revoked
If you use or sell the LumiraDx SARS CoV-2 RNA STAR Complete test, you must stop: the FDA revoked its Emergency Use Authorization at the company's request, so that test can no longer be used for quick COVID-19 diagnosis.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in